0HX7 Stock Chart & Stats
$8.20
-$0.33(-4.02%)
At close: 4:00 PM EDT
$8.20
-$0.33(-4.02%)
Day’s Range― - ―
52-Week Range$3.83 - $14.48
Previous CloseN/A
Volume28.00
Average Volume (3M)3.40K
Market Cap
$35.67M
Enterprise Value-$12.49M
Total Cash (Recent Filing)$118.19M
Total Debt (Recent Filing)$12.85M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 11, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume2,262
30 Day Avg. Volume3,401
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.31
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$25.00Price Target Upside204.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Off-the-shelf PlatformThe allogeneic, off-the-shelf approach could support faster and more standardized treatment delivery than individualized cell therapies if clinical efficacy is validated. A shared platform across cancer indications may also create multiple development opportunities from the same underlying technology.
Prula-cel Clinical EvidencePrula-cel’s reported remission and renal-response outcomes provide meaningful clinical validation for the autoimmune program, while the generally favorable safety profile supports continued development. These results strengthen the case for a pivotal lupus nephritis trial and potential expansion into broader lupus indications.
Conservative LeverageLow leverage limits debt-related financial pressure and preserves more flexibility than a heavily indebted balance sheet would provide. This is valuable for a development-stage biotech because it leaves the company less exposed to mandatory interest and principal obligations while clinical programs advance.
Bears Say
No Commercial RevenueThe absence of meaningful product revenue means the company has not yet demonstrated a commercial earnings engine and remains dependent on clinical progress to create future value. Until a therapy is approved and launched, operating performance will remain driven primarily by research spending and financing needs.
Heavy Cash BurnSustained operating and free-cash-flow deficits require continued access to external funding to support trials and corporate operations. This dependence can constrain strategic flexibility over the next several quarters and makes the company’s ability to advance its pipeline sensitive to financing availability.
Shrinking Equity BaseThe sharply reduced equity base and deeply negative return on equity indicate that cumulative losses are eroding shareholder capital despite modest leverage. Continued value erosion can weaken financial resilience and reduce the resources available to fund development before commercial revenues emerge.
Adicet Bio News
0HX7 FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest share price was $3.83 and its highest was $14.48 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $35.67M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Nov 11, 2026 which is in 14 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on Aug 05, 2026. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$1.692 by -$0.298.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.12%. See more information on Adicet Bio Inc dividends here
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -1.58.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,361,490 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$1.99 in its last earnings report, missing expectations of -$1.692. Following the earnings report the stock price went down -11.868%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in GB:0HX7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (204.88% Upside)
$25.00 (204.88% Upside)
Blogger Sentiment
Bullish
GB:0HX7 Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.59%
12-Months-Change
Fundamentals
Return on Equity
-74.90%
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Adicet Bio Inc
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
0HX7 Stock 12 Month Forecast
Average Price Target
$25.00
▲(204.88% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―